US Government Opposes Proposed Illumina/Grail Merger
Executive Summary
Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.
You may also be interested in...
Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Grail Files For $100M IPO, Plans To Launch Multi-Cancer Early Detection Test In 2021
Grail hopes to launch its Galleri test in 2021 as a laboratory developed test and submit a PMA to the US FDA in 2023.
Illumina Pays Pacific Biosciences $98M To Terminate $1.2Bn Merger Deal
Illumina had planned to acquire Pacific Biosciences to add the company's “long-read” gene sequencing systems to Illumina's own range of "short-read" technologies. However, the UK’s Competition and Markets Authority and the US Federal Trade Commission concluded that the deal would significantly reduce competition in the DNA sequencing market.